Arvinas’ ARV-102 Hits >50% LRRK2 Degradation in Phase 1 Parkinson’s Trial

Overview

• ARV-102 achieved greater than 50% LRRK2 degradation in cerebrospinal fluid after 28 days, with target reduction reached by day 14 and sustained through day 28.
• Cerebrospinal fluid exposure increased with dose, confirming brain penetration for the oral PROTAC degrader.
• Endolysosomal and neuroinflammatory biomarkers associated with Parkinson’s disease and progressive supranuclear palsy declined during treatment.
• Across 20–80 mg once-daily dosing for 28 days, adverse events were mild with no serious events, discontinuations, or deaths reported.
• Arvinas presented the data at AD/PD 2026 and plans a Phase 1b PSP study in the second quarter of 2026, with potential progression to a registrational trial later in the year.